Study suggests biological age can be reduced
A pilot study conducted by TruMe Labs for Ponce de Leon Health suggests that biological age can be reduced, the company reported.
Oblique, Targovax partner on anticancer treatment
Oblique Therapeutics and Targovax are partnering on anticancer treatment by combining their Oncos and Abiprot offerings.
Eurofins DiscoverX expands program with Catalent
Eurofins DiscoverX has expanded its contract research organization certification program for bioassays with Catalent Biologics as the North American provider.
Consortium studies body-on-a-chip technology
The Wake Forest Institute for Regenerative Medicine and Oracle Health Sciences have joined forces to develop a consortium of industry, government, and academic members to study novel approaches to establish drug safety.
Celltex moves COVID-19 prophylactic to clinical trials
Celltex has received approval from the U.S. Food and Drug Administration to investigate the prophylactic efficacy of autologous adipose tissue-derived mesenchymal stem cells against COVID-19.
Entos to begin phase I/II study of COVID-19 vaccine candidate
Entos Pharmaceuticals has selected two lead candidates for a pancoronavirus Fusogenix DNA vaccine (Covigenix) from its prototyping program to initiate phase I/II human clinical trials in late July.
Catalent to provide fill-finish for Moderna's COVID-19 vaccine
Catalent will collaborate with Moderna for large-scale commercial fill-finish manufacturing of Moderna's messenger RNA-based COVID-19 vaccine candidate, mRNA-1273, at Catalent's biologics facility in Bloomington, IN.
CEPI ramps up manufacturing for COVID-19 vaccines
The Coalition for Epidemic Preparedness Innovations (CEPI) signed an agreement with Italy-based Stevanto Group for the supply of 100 million glass vials to hold up to 2 billion doses of a COVID-19 vaccine.
MaxCyte launches Expert cell engineering products
Cell-based medicines and life sciences company MaxCyte has launched a new line of disposable cell engineering products.
ReNeuron to manufacture exosomes for gene therapies
ReNeuron signed a research evaluation agreement with a U.S. biotechnology company for the use of its proprietary exosomes for the delivery of novel gene silencing therapies.